These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22507892)

  • 1. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
    Bonnetain F; Bosset JF; Gerard JP; Calais G; Conroy T; Mineur L; Bouché O; Maingon P; Chapet O; Radosevic-Jelic L; Methy N; Collette L
    Eur J Cancer; 2012 Aug; 48(12):1781-90. PubMed ID: 22507892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
    Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M
    J BUON; 2013; 18(2):385-90. PubMed ID: 23818350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life.
    Kripp M; Wieneke J; Kienle P; Welzel G; Brade J; Horisberger K; Wenz F; Post S; Gencer D; Hofmann WK; Hofheinz RD
    Eur J Surg Oncol; 2012 Jun; 38(6):472-7. PubMed ID: 22349986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of neoadjuvant chemoradiation therapy with oxaliplatin and capecitabine or 5-fluorouracil for locally advanced rectal cancer.
    Lu JY; Xiao Y; Qiu HZ; Wu B; Lin GL; Xu L; Zhang GN; Hu K
    J Surg Oncol; 2013 Sep; 108(4):213-9. PubMed ID: 23913795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
    Vestermark LW; Jensen HA; Pfeiffer P
    Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?
    Mawdsley S; Glynne-Jones R; Grainger J; Richman P; Makris A; Harrison M; Ashford R; Harrison RA; Osborne M; Livingstone JI; MacDonald P; Mitchell IC; Meyrick-Thomas J; Northover JM; Windsor A; Novell R; Wallace M
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):745-52. PubMed ID: 16199310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study.
    Brændengen M; Tveit KM; Bruheim K; Cvancarova M; Berglund Å; Glimelius B
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1017-24. PubMed ID: 20932687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
    Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
    J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
    Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D
    Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy with or without pelvic radiotherapy after simultaneous surgical resection of rectal cancer with liver metastases: analysis of prognosis and patterns of recurrence.
    An HJ; Yu CS; Yun SC; Kang BW; Hong YS; Lee JL; Ryu MH; Chang HM; Park JH; Kim JH; Kang YK; Kim JC; Kim TW
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):73-80. PubMed ID: 22300562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can increasing the dose of radiation by HDR brachytherapy boost following pre operative chemoradiotherapy for advanced rectal cancer improve surgical outcomes?
    Sun Myint A; Mukhopadhyay T; Ramani VS; Perkins K; Snee AJ; Jelley F; Wong H; Lee CD
    Colorectal Dis; 2010 Aug; 12 Suppl 2():30-6. PubMed ID: 20618365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer.
    Ceelen W; Boterberg T; Pattyn P; van Eijkeren M; Gillardin JM; Demetter P; Smeets P; Van Damme N; Monsaert E; Peeters M
    Ann Surg Oncol; 2007 Feb; 14(2):424-31. PubMed ID: 17096057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
    An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR
    Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
    Kim JC; Takahashi K; Yu CS; Kim HC; Kim TW; Ryu MH; Kim JH; Mori T
    Ann Surg; 2007 Nov; 246(5):754-62. PubMed ID: 17968166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
    Lee SH; Lee KC; Choi JH; Oh JH; Baek JH; Park SH; Shin DB
    Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.
    Gunderson LL; Sargent DJ; Tepper JE; Wolmark N; O'Connell MJ; Begovic M; Allmer C; Colangelo L; Smalley SR; Haller DG; Martenson JA; Mayer RJ; Rich TA; Ajani JA; MacDonald JS; Willett CG; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1785-96. PubMed ID: 15067027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.
    Fokas E; Fietkau R; Hartmann A; Hohenberger W; Grützmann R; Ghadimi M; Liersch T; Ströbel P; Grabenbauer GG; Graeven U; Hofheinz RD; Köhne CH; Wittekind C; Sauer R; Kaufmann M; Hothorn T; Rödel C;
    Ann Oncol; 2018 Jul; 29(7):1521-1527. PubMed ID: 29718095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
    Smalley SR; Benedetti JK; Williamson SK; Robertson JM; Estes NC; Maher T; Fisher B; Rich TA; Martenson JA; Kugler JW; Benson AB; Haller DG; Mayer RJ; Atkins JN; Cripps C; Pedersen J; Periman PO; Tanaka MS; Leichman CG; Macdonald JS
    J Clin Oncol; 2006 Aug; 24(22):3542-7. PubMed ID: 16877719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.